Presentation is loading. Please wait.

Presentation is loading. Please wait.

Design Randomisation 1 : 1 Open-label W16 W24 > 18 years

Published byBelinda Blair Modified over 6 years ago

Similar presentations

Presentation on theme: "Design Randomisation 1 : 1 Open-label W16 W24 > 18 years"— Presentation transcript:

1 REVENGE: retreatment with SOF + EBR + GZR + RBV after failure with SOF + (LDV or DCV or SMV)
Design Randomisation 1 : 1 Open-label W16 W24 > 18 years HCV infection Genotype 1 or 4 Failure to a prior therapy with SOF ± RBV + (SMV or DCV or LDV) with documented presence of NS5A or NS3 RASs at failure Fibrosis at any stage No HBV or HIV co-infection N = 12 SOF + EBR + GZR + RBV SOF + EBR + GZR + RBV N = 13 SOF: 400 mg ; EBR: 50 mg ; GZR: 100 mg Objective SVR4 (HCV RNA < 15 IU/mL) REVENGE De Ledinghen V. AASLD 2016, Abs. LB-18

2 Baseline characteristics and outcome (SVR4)
REVENGE: retreatment with SOF + EBR + GZR + RBV after failure with SOF + (LDV or DCV or SMV) Baseline characteristics and outcome (SVR4) SOF + EBR + GZR + RBV 16 weeks, N = 12 24 weeks, N = 13 Age, years, mean 61 59 Female,% 31 15 BMI, kg/m2, mean 29.9 26.6 Genotype, % 1a 1b/1d 4 23.1 61.5 15.4 38.5 30.8 HCV RNA log10 IU/mL, median 6.1 6.2 Fibroscan (kPa), % ≤ 9.5 0.5-20 > 20 23 31 46 54 Previous HCV treatment, % SOF + LDV SOF + DCV SOF + SMV 69 RAS, n NS5A NS3 13 11 2 SVR4 100% REVENGE De Ledinghen V. AASLD 2016, Abs. LB-18

3 REVENGE: retreatment with SOF + EBR + GZR + RBV after failure with SOF + (LDV or DCV or SMV)
Safety Serious adverse events, N = 9, in 7 patients (28%) : right hypochondrium pain, dermo-hypodermitis, decompensated cirrhosis, hepatocellular carcinoma (HCC) (N = 3), liver transplantation for HCC, liver biopsy of nodule and septic shock with acute kidney failure None were related to study drugs Of the 3 HCC, 2 were recurrences during the treatment phase, 1 was de novo 3 days after the end of treatment Hemoglobin < 10 g/dL, N = 4 (16%) ; < 8.5 g/dL in 1 patient REVENGE De Ledinghen V. AASLD 2016, Abs. LB-18

4 REVENGE: retreatment with SOF + EBR + GZR + RBV after failure with SOF + (LDV or DCV or SMV)
Summary Retreating patients who failed a DAA-based regimen with NS5A/NS3 RASs with the combination of SOF + GZR + EBR + RBV for 16 weeks is efficacious and represent an interesting option Safety needs to be monitored cautiously in these patients with a severe disease REVENGE De Ledinghen V. AASLD 2016, Abs. LB-18

Download ppt "Design Randomisation 1 : 1 Open-label W16 W24 > 18 years"

Similar presentations

ALLY-1  Design  Objective –SVR 12 (HCV RNA < 25 IU/ml) in genotype 1 DCV 60 mg qd + SOF 400 mg qd + RBV DCV 60 mg qd + SOF 400 mg qd + RBV Not randomised.

ALLY-1  Design  Objective –SVR 12 (HCV RNA < 25 IU/ml) in genotype 1 DCV 60 mg qd + SOF 400 mg qd + RBV DCV 60 mg qd + SOF 400 mg qd + RBV Not randomised.
UNITY-1 DCV/ASV/BCB No randomisation Open-label UNITY-1 Study: daclatasvir/asunaprevir/beclabuvir in genotype 1 without cirrhosis  Design W12 ≥ 18 years.

UNITY-1 DCV/ASV/BCB No randomisation Open-label UNITY-1 Study: daclatasvir/asunaprevir/beclabuvir in genotype 1 without cirrhosis  Design W12 ≥ 18 years.
SIRIUS Placebo LDV/SOF + placebo Randomisation* 1 : 1 Double-blind SIRIUS Study: LDV/SOF ± RBV for genotype 1 and cirrhosis with non response to prior.

SIRIUS Placebo LDV/SOF + placebo Randomisation* 1 : 1 Double-blind SIRIUS Study: LDV/SOF ± RBV for genotype 1 and cirrhosis with non response to prior.
SMV + DCV + SOF Open label Chronic HCV infection Genotype 1 or 4 Treatment-naïve or pre-treated with PEG-IFN ± RBV Portal hypertension or liver decompensation.

SMV + DCV + SOF Open label Chronic HCV infection Genotype 1 or 4 Treatment-naïve or pre-treated with PEG-IFN ± RBV Portal hypertension or liver decompensation.
> 18 years Chronic HCV infection Genotype 1 Failure (relapse) to 4, 6 or 8 weeks of GZR/EBR + SOF in C-SWIFT Part A Compensated cirrhosis assessed by liver.

> 18 years Chronic HCV infection Genotype 1 Failure (relapse) to 4, 6 or 8 weeks of GZR/EBR + SOF in C-SWIFT Part A Compensated cirrhosis assessed by liver.
Forns X. J Hepatology 2015; 63: 564-72 C-SALVAGE Study: grazoprevir + elbasvir + RBV in genotype 1 with failure to PI-based regimen –NS3 and NS5A RAVs.

Forns X. J Hepatology 2015; 63: C-SALVAGE Study: grazoprevir + elbasvir + RBV in genotype 1 with failure to PI-based regimen –NS3 and NS5A RAVs.
OBV/PTV/r + DSV Open label Chronic HCV infection Genotype 1 Treatment-naïve HCV RNA > 1,000 IU/ml Chronic kidney disease with eGFR < 30 ml/min/1.73m 2.

OBV/PTV/r + DSV Open label Chronic HCV infection Genotype 1 Treatment-naïve HCV RNA > 1,000 IU/ml Chronic kidney disease with eGFR < 30 ml/min/1.73m 2.
No randomisation Open-label 18-70 years HCV genotype 1 Naïve or null-response to PEG-IFN + RBV HCV RNA > 10,000 IU/ml No cirrhosis No HBV or HIV co-infection.

No randomisation Open-label years HCV genotype 1 Naïve or null-response to PEG-IFN + RBV HCV RNA > 10,000 IU/ml No cirrhosis No HBV or HIV co-infection.
Asselah T. AASLD 2015, Abs. 1179 OSIRIS  Design SMV + PEG-IFN + RBV Open label Chronic HCV infection Genotype 4 Treatment-naïve Mild to moderate fibrosis.

Asselah T. AASLD 2015, Abs OSIRIS  Design SMV + PEG-IFN + RBV Open label Chronic HCV infection Genotype 4 Treatment-naïve Mild to moderate fibrosis.
 Objective –SVR 12 (HCV RNA < 25 IU/ml), with 95% CI, next observation carried backward DCV + SOF + RBV Randomised* 1:1 Open-label ALLY-3+ study: DCV.

 Objective –SVR 12 (HCV RNA < 25 IU/ml), with 95% CI, next observation carried backward DCV + SOF + RBV Randomised* 1:1 Open-label ALLY-3+ study: DCV.
LDV/SOF Failure Open-label W24 Chronic HCV infection Genotype 1 Failure to achieve SVR on LDV/SOF-containing regimen Compensated cirrhosis (liver biopsy.

LDV/SOF Failure Open-label W24 Chronic HCV infection Genotype 1 Failure to achieve SVR on LDV/SOF-containing regimen Compensated cirrhosis (liver biopsy.
SOF/VEL 400/100 mg qd N = 120 W12 SOF + RBV > 18 years Chronic HCV infection Genotype 2 Naïve or pre-treatment with IFN-based regimen Compensated cirrhosis.

SOF/VEL 400/100 mg qd N = 120 W12 SOF + RBV > 18 years Chronic HCV infection Genotype 2 Naïve or pre-treatment with IFN-based regimen Compensated cirrhosis.
 Objective –SVR 12 (HCV RNA < 25 IU/ml), by ITT OBV/PTV/r + DSV + SOF +RBV Open-label W24 ≥ 18 years Chronic HCV Genotype 1 Prior failure on DAA-regimen.

 Objective –SVR 12 (HCV RNA < 25 IU/ml), by ITT OBV/PTV/r + DSV + SOF +RBV Open-label W24 ≥ 18 years Chronic HCV Genotype 1 Prior failure on DAA-regimen.
 Objective –SVR 12 (HCV RNA < 25 IU/ml), by ITT OBV/PTV/r + SOF + RBV OBV/PTV/r + SOF Not randomised Open-label QUARTZ-II Study: OBV/PTV/r + SOF for HCV.

 Objective –SVR 12 (HCV RNA < 25 IU/ml), by ITT OBV/PTV/r + SOF + RBV OBV/PTV/r + SOF Not randomised Open-label QUARTZ-II Study: OBV/PTV/r + SOF for HCV.
No HBV or HIV co-infection

No HBV or HIV co-infection
LDV/SOF Randomisation * 1:1 Open-label ≥ 20 years, Japanese Chronic HCV infection Genotype 1 HCV RNA ≥ 100 000 IU/ml Treatment-naive, or pre-treated Compensated.

LDV/SOF Randomisation * 1:1 Open-label ≥ 20 years, Japanese Chronic HCV infection Genotype 1 HCV RNA ≥ IU/ml Treatment-naive, or pre-treated Compensated.
No cirrhosis or compensated cirrhosis * No HBV or HIV coinfection

No cirrhosis or compensated cirrhosis * No HBV or HIV coinfection
Genotype 1 HCV infection Stable immunosuppressive therapy

Genotype 1 HCV infection Stable immunosuppressive therapy
Design Randomisation* 1 : 1 Open-label W8 W12

Design Randomisation* 1 : 1 Open-label W8 W12
ARV-trial.com RUBY-II Study: ombitasvir/paritaprevir/ritonavir + dasabuvir for HCV genotype 1a or 4 with severe renal impairment Design Open label W12.

ARV-trial.com RUBY-II Study: ombitasvir/paritaprevir/ritonavir + dasabuvir for HCV genotype 1a or 4 with severe renal impairment Design Open label W12.

Similar presentations

Ads by Google